ACRV
Acrivon Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
2.20
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.17
Prev close
2.20
Day high
2.31
Day low
2.18
Volume
361.33K
Market cap
$94.71M
P/E (TTM)
—
52W range
1.27 – 3.56
Day trading desk
Gap from prior close
-1.36%
Prior close 2.20
VWAP
2.24
-1.74% from price
Relative volume
0.88×
Normal
Session range
6.94%
2.16 – 2.31
Position in range
27%
Near session low
ATR (14D)
0.13
5.86% of price
Prior day high
2.37
PDH
Prior day low
2.17
PDL
Bid / ask spread
—
Quote not published
Session volume
362.85K
Avg 414.61K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+13.33%
+14.7%
1M
+32.34%
+28.6%
3M
+23.46%
+20.4%
6M
+44.44%
+33.4%
YTD
-8.30%
-20.6%
1Y
+70.00%
+50.0%
3Y
-80.37%
-154.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ACRV open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+4.47M
Net buying
Buy transactions
15
4.47M shares
Sell transactions
4
2.30K shares
Net transactions
+19
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
6.58M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | MILLER MARY Officer |
SELL | 185 | $372 | Direct |
| Aug 18, 26 | GAMELIN ERICK Officer |
SELL | 400 | $804 | Direct |
| Aug 4, 26 | LEVY ADAM D. Chief Financial Officer |
SELL | 1.14K | $1.79K | Direct |
| Jul 21, 26 | MILLER MARY Officer |
SELL | 573 | $1.01K | Direct |
| May 18, 26 | TOMSICEK MICHAEL JOHN Director |
STOCK | 9.37K | $0 | Direct |
| May 18, 26 | MIRZA MANSOOR RAZA Officer |
STOCK | 38.82K | $0 | Direct |
| May 18, 26 | SHACHAM SHARON Director |
STOCK | 9.37K | $0 | Direct |
| May 18, 26 | MAGOVCEVIC-LIEBISCH IVANA Director |
STOCK | 9.37K | $0 | Direct |
| May 18, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
STOCK | 9.37K | $0 | Indirect |
| May 18, 26 | BAUM CHARLES M Director |
STOCK | 9.37K | $0 | Direct |
| May 18, 26 | DIROCCO DEREK Director |
STOCK | 9.37K | $0 | Direct |
| May 18, 26 | MILLER MARY Officer |
STOCK | 49.83K | $0 | Direct |
| May 18, 26 | DEVROE ERIC Chief Operating Officer |
STOCK | 72.98K | $0 | Direct |
| May 18, 26 | BLUME-JENSEN PETER Chief Executive Officer |
STOCK | 252.80K | $0 | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BLUME-JENSEN PETER |
Chief Executive Officer | — | Stock Award(Grant) |
DEVROE ERIC |
Chief Operating Officer | 146.95K | Stock Award(Grant) |
GAMELIN ERICK |
Officer | 52.59K | Sale |
LEVY ADAM D. |
Chief Financial Officer | 66.01K | Sale |
MILLER MARY |
Officer | 82.01K | Sale |
MIRZA MANSOOR RAZA |
Officer | 38.82K | Stock Award(Grant) |
PALANI SANTHOSH |
Director | 9.37K | Stock Award(Grant) |
PERCEPTIVE ADVISORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
PETERSON KATHARINE |
Officer | 18.13K | Stock Award(Grant) |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
Fundamentals
Market cap$94.71M
Enterprise value$6.86M
Revenue (TTM)—
Gross profit—
EBITDA$-76.88M
Net income$-74.22M
EPS (TTM)$-1.88
Free cash flow$-39.82M
Total cash$89.96M
Total debt$2.12M
Book value / share$2.02
Shares outstanding42.85M
Float25.68M
Short % of float4.73%
Dividend yield—
Beta (5Y)1.86
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.31
PEG ratio—
Price / sales—
Price / book1.09
EV / revenue—
EV / EBITDA-0.09
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-64.63%
Return on assets-38.02%
Debt / equity2.44
Current ratio7.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $59.99M | $63.99M | $46.02M | $23.95M | -6.3% |
| Selling, general & admin | $24.12M | $25.21M | $21.08M | $8.71M | -4.3% |
| Total operating expense | $84.11M | $89.20M | $67.10M | $32.66M | -5.7% |
| Operating income | -$84.11M | -$89.20M | -$67.10M | -$32.66M | +5.7% |
| Net interest income | $6.48M | $9.20M | $7.04M | — | -29.6% |
| Pre-tax income | -$77.91M | -$80.56M | -$60.39M | -$31.17M | +3.3% |
| Net income | -$77.91M | -$80.56M | -$60.39M | -$31.17M | +3.3% |
| Net income to common | -$77.91M | -$80.56M | -$60.39M | -$31.17M | +3.3% |
| Basic EPS | -2.02 | -2.38 | -2.74 | -7.56 | +15.1% |
| Diluted EPS | -2.02 | -2.38 | -2.74 | -7.56 | +15.1% |
| EBIT | -$84.11M | -$89.20M | -$67.10M | -$32.66M | +5.7% |
| EBITDA | -$82.76M | -$88.19M | -$66.57M | -$32.29M | +6.2% |
| Basic shares | 38.51M | 33.79M | 22.08M | 4.12M | +14.0% |
| Diluted shares | 38.51M | 33.79M | 22.08M | 4.12M | +14.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $41.50M | $39.82M | $36.02M | $29.52M | +4.2% |
| Cash & short-term investments | $118.58M | $179.48M | $127.46M | $127.75M | -33.9% |
| Total current assets | $120.44M | $181.63M | $129.69M | $132.09M | -33.7% |
| Property, plant & equipment | $7.42M | $8.03M | $7.91M | $6.86M | -7.6% |
| Total assets | $129.72M | $196.59M | $138.26M | $181.23M | -34.0% |
| Total current liabilities | $15.66M | $17.21M | $13.30M | $6.52M | -9.0% |
| Total debt | $2.71M | $3.65M | $4.64M | $4.96M | -25.7% |
| Total liabilities | $17.20M | $19.80M | $17.07M | $10.75M | -13.1% |
| Retained earnings | -$274.88M | -$196.98M | -$116.42M | -$56.03M | -39.6% |
| Shareholder equity | $112.52M | $176.79M | $121.19M | $170.47M | -36.4% |
| Working capital | $104.78M | $164.41M | $116.39M | $125.58M | -36.3% |
| Net tangible assets | $112.52M | $176.79M | $121.19M | $170.47M | -36.4% |
| Shares issued | 31.65M | 31.23M | 22.52M | 21.92M | +1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$77.91M | -$80.56M | -$60.39M | -$31.17M | +3.3% |
| Depreciation & amortisation | $1.36M | $1.01M | $536.00K | $364.00K | +34.8% |
| Stock-based compensation | $14.72M | $14.29M | $11.62M | $2.19M | +3.0% |
| Change in working capital | -$2.43M | $2.44M | $8.14M | -$1.53M | -199.5% |
| Operating cash flow | -$63.66M | -$65.67M | -$42.64M | -$30.12M | +3.1% |
| Capital expenditure | -$1.67M | -$2.77M | -$1.29M | -$2.17M | +39.7% |
| Investing cash flow | $66.10M | -$51.77M | $50.72M | -$141.68M | +227.7% |
| Financing cash flow | -$749.00K | $121.03M | -$1.55M | $101.71M | -100.6% |
| Free cash flow | -$65.33M | -$68.44M | -$43.93M | -$32.28M | +4.5% |
| End cash position | $41.70M | $40.02M | $36.43M | $29.91M | +4.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $15.17M | $14.75M | $13.65M | $16.18M | $15.41M | — | +2.8% |
| Selling, general & admin | $4.74M | $5.37M | $6.04M | $6.47M | $6.25M | — | -11.8% |
| Total operating expense | $19.90M | $20.12M | $19.69M | $22.65M | $21.66M | — | -1.1% |
| Operating income | -$19.90M | -$20.12M | -$19.69M | -$22.65M | -$21.66M | — | +1.1% |
| Net interest income | $989.00K | $1.25M | $1.51M | $1.73M | $2.00M | — | -20.7% |
| Pre-tax income | -$19.04M | -$18.98M | -$18.23M | -$21.01M | -$19.68M | — | -0.3% |
| Net income | -$19.04M | -$18.98M | -$18.23M | -$21.01M | -$19.68M | — | -0.3% |
| Net income to common | -$19.04M | -$18.98M | -$18.23M | -$21.01M | -$19.68M | — | -0.3% |
| Basic EPS | -0.49 | — | -0.47 | -0.55 | -0.51 | -0.60 | — |
| Diluted EPS | -0.49 | — | -0.47 | -0.55 | -0.51 | -0.60 | — |
| EBIT | -$19.90M | -$20.12M | -$19.69M | -$22.65M | -$21.66M | — | +1.1% |
| EBITDA | -$19.52M | -$19.75M | -$19.34M | -$22.31M | -$21.35M | — | +1.2% |
| Basic shares | 38.72M | — | 38.56M | 38.46M | 38.35M | 38.24M | — |
| Diluted shares | 38.72M | — | 38.56M | 38.46M | 38.35M | 38.24M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.06M | $41.50M | $35.41M | $41.90M | $39.15M | -17.9% |
| Cash & short-term investments | $97.74M | $118.58M | $129.25M | $137.42M | $149.63M | -17.6% |
| Total current assets | $99.22M | $120.44M | $130.36M | $138.41M | $151.33M | -17.6% |
| Property, plant & equipment | $6.91M | $7.42M | $7.98M | $8.12M | $7.98M | -6.9% |
| Total assets | $107.83M | $129.72M | $145.30M | $158.58M | $176.35M | -16.9% |
| Total current liabilities | $11.05M | $15.66M | $14.89M | $13.43M | $13.55M | -29.4% |
| Total debt | $2.42M | $2.71M | $2.99M | $3.26M | $3.51M | -10.9% |
| Total liabilities | $12.32M | $17.20M | $16.70M | $15.55M | $15.96M | -28.4% |
| Retained earnings | -$293.92M | -$274.88M | -$255.90M | -$237.66M | -$216.66M | -6.9% |
| Shareholder equity | $95.52M | $112.52M | $128.60M | $143.04M | $160.39M | -15.1% |
| Working capital | $88.17M | $104.78M | $115.47M | $124.98M | $137.78M | -15.9% |
| Net tangible assets | $95.52M | $112.52M | $128.60M | $143.04M | $160.39M | -15.1% |
| Shares issued | 38.75M | 31.65M | 31.55M | 31.45M | 31.35M | +22.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$19.04M | -$18.98M | -$18.23M | -$21.01M | -$19.68M | -0.3% |
| Depreciation & amortisation | $383.00K | $361.00K | $349.00K | $335.00K | $311.00K | +6.1% |
| Stock-based compensation | $2.18M | $3.09M | $3.91M | $3.93M | $3.79M | -29.4% |
| Change in working capital | -$4.49M | -$99.00K | $1.47M | $52.00K | -$3.85M | -4,439.4% |
| Operating cash flow | -$20.54M | -$15.24M | -$12.28M | -$16.61M | -$19.54M | -34.8% |
| Capital expenditure | -$14.00K | -$219.00K | -$899.00K | -$493.00K | -$58.00K | +93.6% |
| Investing cash flow | $13.13M | $21.52M | $5.91M | $19.45M | $19.21M | -39.0% |
| Financing cash flow | -$33.00K | -$192.00K | -$117.00K | -$97.00K | -$343.00K | +82.8% |
| Free cash flow | -$20.55M | -$15.46M | -$13.18M | -$17.10M | -$19.59M | -33.0% |
| End cash position | $34.26M | $41.70M | $35.61M | $42.10M | $39.35M | -17.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.50 | -0.43 | +13.5% |
| Mar 2026 | -0.52 | -0.49 | +5.8% |
| Dec 2025 | -0.46 | -0.49 | -7.4% |
| Sep 2025 | -0.58 | -0.47 | +19.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.45 | 4 | $0 | 0.0% |
| Next quarter | -0.48 | 4 | $0 | 0.0% |
| Current year | -1.89 | 4 | $0 | 0.0% |
| Next year | -1.69 | 6 | $0 | 0.0% |
Analyst targets & ownership
Mean target$11.50
High target$19.00
Low target$7.00
Implied upside422.73%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy3 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders15.36%
Held by institutions50.34%
Institutions holding57
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.99
+10.61% from price
SMA 20
1.78
+24.09% from price
SMA 50
1.75
+26.43% from price
SMA 100
1.73
+26.85% from price
SMA 200
1.86
+19.08% from price
EMA 12
2.00
+10.21% from price
EMA 26
1.86
+18.13% from price
EMA 50
1.79
+22.79% from price
RSI (14)
67.4
Neutral
MACD (12,26,9)
0.13
Hist 0.07
ATR (14)
0.13
5.83% of price
Realised vol 30D
84.4%
Annualised
Bollinger upper
2.31
20, 2σ
Bollinger lower
1.25
20, 2σ
50 / 200 cross
Death
1.75 vs 1.86
Trend bias
Above 200
+19.08%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.97
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
84.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-57.1%
Peak to trough
Max drawdown 5Y
-95.5%
Peak to trough
ATR 14
0.13
5.83% of price
Beta (reported)
1.86
5Y monthly, from filing
Short interest
Shares short
1.36M
Prior 2.84M
Change vs prior
-52.3%
Shorts covering
% of float
4.73%
Normal
% of shares out
3.17%
Against total outstanding
Days to cover
3.0
Liquid
Float
25.68M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 9, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Nov 25, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 14, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 16, 25 | Jones Trading | DOWNGRADE | Buy | Hold |
| May 15, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Mar 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 28, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Mar 26, 25 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Mar 26, 25 | Citizens Capital Markets | MAINTAINED | Market Outperform | Market Outperform |
| Mar 26, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 31, 25 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Nov 14, 24 | BMO Capital | MAINTAINED | Outperform | Outperform |
SEC filings
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-06-17
Proxy Statements
DEFA14A · 2026-05-22
Corporate Changes & Voting Matters
8-K · 2026-05-13
Proxy Statements
DEF 14A · 2026-04-30
Periodic Financial Reports
10-K · 2026-03-19
Corporate Changes & Voting Matters
8-K · 2026-03-02
Corporate Changes & Voting Matters
8-K · 2026-02-27
Headlines
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
GlobeNewswire · 11d ago
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
GlobeNewswire · 18d ago
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
GlobeNewswire · 33d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.